Posts Tagged ‘Melissa Fisher’

CorDynamics’ Melissa Fisher takes on Shamrock Shuffle Chicago 2012

Posted by Theresa Gralinski, Marketing Director at CorDynamics on March 14th, 2012

CorDynamics is sponsoring resident runner and our operations manager, Melissa Fisher, in the upcoming Shamrock Shuffle Chicago 2012 — the largest 8K in the world with 40,000 participants expected.

Melissa Fisher Runs For the Pot of Gold — Shamrock Shuffle Chicago 2012

In a city with such a rich Irish heritage it dyes the river green, running this Shamrock Shuffle has become a Chicago tradition.

CorDynamic's Melissa Fisher takes on Shamrock Shuffle Chicago 2012

Runners have to have heart in more ways than one as running here this time of year can turn into its own form of March Madness.

“Because this race is so early in the year, it is hard to predict the weather,” admits Melissa. “When I ran the race last year, it was sunny and 70. But, there have been many years where it has been snowy, cold and not to mention windy.”

Even with its cold winters, Chicago ranked on the Forbes Top-10 Cities in America For Runners, for what it has to offer in the spring, summer and fall months.

A gorgeous 18-mile path along Lake Michigan and flat terrain.

Plenty of competition—different races are held on back-to-back days on weekends during prime running season.

Vibrant running community—training clubs, running associations and social clubs that often lead to post-run beers at one of the city’s many pubs.

The good news about training in Chicago for Chicago races: You are ready for anything.

“It was so windy yesterday, I felt like I was running backwards,” says Melissa. “During my training run two weekends ago, it was snowing, but it was pretty.”

I’m pretty sure I speak for the majority of the CorD team when I say: Thanks Melissa for taking on this challenge on our behalf.

May the road rise up to meet you, may the wind be always at your back and may your heart-healthy lifestyle carry you far….

Filed under: About Us, Management Team | No Comments

Pulmonary Arterial Hypertension in Non-Human Primates

Posted by Michael Gralinski, Chief Executive Officer at CorDynamics on September 04th, 2009

My team and I are returning from the 2009 Safety Pharmacology Society meeting in Strasbourg, France. With us was our lead veterinary technician, Ms. Melissa Fisher, who was awarded a Junior Investigator Travel Award for her work with her colleagues developing a model of hypoxic pulmonary vasoconstriction / pulmonary arterial hypertension (PAH) in the cynomolgus non-human primate.

After conducting more than 18 experiments interrogating the intertwining roles of anesthesia, arterial oxygen tension, and surgical plane in the stability of the model, our labs are now providing clients with a paradigm that defines a compound’s ability to selectively reduce pulmonary artery pressure in the presence of existing PAH using non-human primates. Building on our previous work in the canine and rat, Melissa rose to the challenge and coordinated the experiments to bolster the disheartening lack of scientific literature in this arena. There are no reliable publications describing PAH in the non-human primate; only a few aged papers detail measurement of arterial oxygen tension or other tangential parameters having a relationship to pulmonary function in this species.

Looking at the graphs below, we’ve defined the selectivity for prostacyclin (a well-characterized vasodilator) in this model. The experiments could not have gone any better. We previously demonstrated that 10% inhaled oxygen is sufficient to induce a greater than 30% increase in pulmonary artery pressure. At the lowest studied dose of prostacyclin (1.5 μg/kg/min), there was no appreciable reduction in either pulmonary artery pressure or systemic arterial pressure during the hypoxic vasoconstriction.

However, at 15 μg/kg/min, our labs uncovered the differential vasoactivity of prostacyclin on the pulmonary architecture.

As a result of these data, we are highly confident that we can uncover similar properties in proprietary molecules; improvements would likely involve either an augmented differential response or via longer pharmacodynamic action than prostacyclin.

Melissa was excited to accept the award and present the team’s research in France. We believe these paradigms can be of tremendous value as the industry looks toward meeting patient needs in the area of pulmonary hypertension.

Filed under: Hemodynamics, Pulmonary Arterial Hypertension | No Comments